2022
Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis.
Ragon B, D'Souza A, Estrada-Merly N, Fraser R, George G, Gowda L, Shah N, Qazilbash M, Kumar S, Horowitz M, Usmani S, Shah M. Impact of second primary malignancy post-autologous hematopoietic stem cell transplantation on outcomes of multiple myeloma: A CIBMTR analysis. Journal Of Clinical Oncology 2022, 40: 8057-8057. DOI: 10.1200/jco.2022.40.16_suppl.8057.Peer-Reviewed Original ResearchSecond hematological malignanciesSecond primary malignanciesTherapy-related myeloid neoplasmsOverall survivalMultiple myelomaAllogeneic HCTMaintenance therapyDevelopment of SPMsAutologous hematopoietic stem cell transplantMarrow Transplant Research registryThree-year cumulative incidenceHematopoietic stem cell transplantHematopoietic stem cell transplantationMelphalan conditioning regimenMedian overall survivalStem cell transplantStem cell transplantationAuto-HCTCIBMTR analysisInferior PFSMedian followAllo-SCTCommonest causeConditioning regimenKarnofsky score
2020
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*
Bewersdorf JP, Shallis RM, Gowda L, Wei W, Hager K, Isufi I, Kim TK, Pillai MM, Seropian S, Podoltsev NA, Gore SD, Siddon AJ, Zeidan AM. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience*. Leukemia & Lymphoma 2020, 61: 2180-2190. PMID: 32362171, PMCID: PMC7603787, DOI: 10.1080/10428194.2020.1759051.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMedian overall survivalTherapy-related malignanciesOverall survivalMyelodysplastic syndromeMyeloid leukemiaAllogeneic hematopoietic stem cell transplantLonger median overall survivalSingle-center retrospective studyComplex karyotypeHematopoietic stem cell transplantIntensive chemotherapy approachesYale Cancer CenterCharacteristics of patientsSingle-center experienceMinority of patientsStem cell transplantLong-term survivalLow response rateIntensive chemotherapyCenter experienceClinicopathologic characteristicsAdverse prognosisAML patientsCell transplant